Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
NCT ID: NCT02398188
Last Updated: 2019-01-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
793 participants
INTERVENTIONAL
2015-04-09
2015-10-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Study to Evaluate Retreatment With LIPO-202
NCT02397525
Evaluation of Procedural Analgesia for Liposonix Treatment
NCT01993238
Condition of Submental Fullness and Treatment Outcomes Registry
NCT02438813
Cryolipolysis and Subcision for Treatment of Cellulite
NCT01209767
Shockwave Therapy (SWT)
NCT03986983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LIPO-202
Experimental arm
LIPO-202
Placebo
Placebo comparator
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LIPO-202
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of providing written consent.
* BMI \< 30 kg/m2
* Stable diet and exercise routine
* Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat
Exclusion Criteria
* Plan on starting a weight loss or exercise program during the study.
* Known hypersensitivity to study drugs
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neothetics, Inc
INDUSTRY
Evofem Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria Feldman
Role: STUDY_DIRECTOR
Neothetics, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Total Skin and Beauty Dermatology Center
Birmingham, Alabama, United States
Stoll Dermatology of Beverly Hills
Beverly Hills, California, United States
Diagnamics, Inc.
Encinitas, California, United States
Ablon Skin Institute And Research Center
Manhattan Beach, California, United States
Dermatology Specialists, Inc.
Oceanside, California, United States
Rancho Mirage Dermatology
Rancho Mirage, California, United States
Faces Plus
San Diego, California, United States
Therapeutics Clinical Research
San Diego, California, United States
Syrentis Clinical Research
Santa Ana, California, United States
Colorado Medical Research Center
Denver, Colorado, United States
The Savin Center, PC
New Haven, Connecticut, United States
Altus Research
Lake Worth, Florida, United States
The Miami Institute
Miami, Florida, United States
Baumann Cosmetic and Research Institute
Miami, Florida, United States
Miami Research Associates
South Miami, Florida, United States
Clinical Research of West Florida, Inc.
Tampa, Florida, United States
DeNova Research
Chicago, Illinois, United States
Laser and Skin Surgery Center of Indiana
Carmel, Indiana, United States
South Bend Clinic
South Bend, Indiana, United States
SkinCare Physicians
Chestnut Hill, Massachusetts, United States
Zel Skin & Laser Specialist, LLC
Edina, Minnesota, United States
Mercy Health Research
Washington, Missouri, United States
Image Dermatology
Montclair, New Jersey, United States
Sadick Research Group
New York, New York, United States
Wake Research Associates
Raleigh, North Carolina, United States
Oregon Medical Research Center
Portland, Oregon, United States
Chaddsford Dermatology
Chadds Ford, Pennsylvania, United States
Paddington Testing Co., Inc.
Philadelphia, Pennsylvania, United States
Society Hill Dermatology
Philadelphia, Pennsylvania, United States
Tennessee Clinical Research Center
Nashville, Tennessee, United States
DermResearch Inc.
Austin, Texas, United States
Modern Research Associates, PLLC
Dallas, Texas, United States
Suzanne Bruce and Associates, P.A., The Center for Skin Research
Houston, Texas, United States
Austin Institute Clinical Research
Pflugerville, Texas, United States
Premier Clinical Research
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIPO-202-CL-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.